Business Context and Reporting Period
Jasper Therapeutics, Inc. filed this Form 8-K on September 29, 2021, reporting events occurring principally on September 24, 2021. The filing documents the completion of the business combination between Amplitude Healthcare Acquisition Corporation, a former special purpose acquisition company, and Old Jasper. AMHC changed its name to Jasper Therapeutics, Inc., and Old Jasper became a wholly owned subsidiary named Jasper Tx Corp. The transaction closed at an agreed Old Jasper equity value of $275.0 million.
Jasper ceased to be a shell company and began trading on Nasdaq under the symbols JSPR for common stock and JSPRW for public warrants, beginning September 27, 2021.
Key Financial and Capitalization Metrics
- PIPE financing: 10,000,000 shares were issued at $10.00 per share for aggregate gross proceeds of $100.0 million. Affiliates of the sponsor funded $28.35 million.
- Redemptions: Holders redeemed 9,262,099 AMHC Class A shares for approximately $92.7 million, at $10.0088193 per share.
- Shares issued at closing: 24,778,409 shares of New Jasper Common Stock were issued to former Old Jasper stockholders, and 10,000,000 shares were issued to PIPE investors.
- Post-closing capitalization: 36,520,288 shares of voting common stock and 1,296,022 shares of non-voting common stock were outstanding. An additional 2,721,557 shares were subject to outstanding options, and 611,818 shares were subject to restricted share awards.
- Public warrants: 5,000,000 public warrants were outstanding immediately after closing, with an exercise price of $11.50 per share.
- Transaction valuation: Old Jasper’s equity value was contractually set at $275.0 million; the filing does not provide a current enterprise value, cash balance, debt balance, revenue, net loss, cash flow, or operating margin in the provided text.
- Dividends: The Company has not paid cash dividends and does not anticipate paying them in the foreseeable future.
Material Changes Versus the Prior Comparable Period
- AMHC completed its merger with Old Jasper, resulting in Jasper Therapeutics becoming the public company and successor registrant.
- AMHC Class B shares converted into Class A shares, and the outstanding AMHC Class A shares were converted into New Jasper voting common stock.
- The sponsor forfeited 200,000 shares and received 2,300,000 New Jasper voting shares at closing, including 1,050,000 shares subject to performance-based escrow provisions.
- Former AMHC directors and executive officers departed, and Jasper appointed a new six-member board and new executive leadership team.
- WithumSmith+Brown, PC was dismissed as the independent auditor, and PricewaterhouseCoopers LLP was appointed for the fiscal year ending December 31, 2021.
- The filing identifies a prior material weakness involving accounting for warrants issued in AMHC’s initial public offering, which led to a restatement of AMHC’s financial statements.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing provides no quantitative revenue, earnings, cash-flow, liquidity, debt, or operating guidance.
- Management’s outlook is focused on researching and developing product candidates, conducting clinical trials, obtaining regulatory approvals, securing financing, maintaining intellectual-property protection, and preserving manufacturing and licensing arrangements.
- Key stated risks include clinical-development timing and success, regulatory approval, future financing needs, competition, intellectual-property claims, reliance on license and manufacturing arrangements, Nasdaq listing and trading liquidity, employee retention, growth management, and the effects of COVID-19.
- Earnout: The 1,050,000 sponsor earnout shares may be released over three years if the applicable volume-weighted average stock price reaches $11.50, $15.00, and $18.00 thresholds over specified trading periods.
- Registration rights and lock-up: Certain holders received resale registration rights, while transfers of specified securities are generally restricted for 180 days after closing, subject to exceptions.
- Equity plans: The 2021 Equity Incentive Plan initially reserves 4,400,000 shares and provides for potential annual increases. The Employee Stock Purchase Plan initially reserves 550,000 shares and also provides for potential annual increases.
- Executive compensation: Initial annual base salaries were $530,000 for William Lis, $400,000 for Jeet Mahal, and $455,274.59 for Kevin Heller, with target annual bonuses of 50%, 40%, and 40%, respectively.
Important Facts an Investor Should Verify
- Review the audited and unaudited Old Jasper financial statements and the unaudited pro forma combined financial statements incorporated from the definitive proxy statement and Exhibit 99.2.
- Verify post-closing cash, cash runway, liabilities, debt, operating expenses, and expected financing requirements, which are not clearly stated in this filing text.
- Assess dilution from outstanding options, restricted awards, public warrants, PIPE shares, earnout shares, and the newly approved equity plans.
- Review the prior warrant-accounting material weakness and the auditor transition from Withum to PwC.
- Examine the registration rights, 180-day lock-up, sponsor earnout conditions, and potential future resale supply.
- Evaluate clinical, regulatory, intellectual-property, licensing, manufacturing, and financing risks described in the definitive proxy statement’s risk factors.